RU2015148010A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2015148010A3 RU2015148010A3 RU2015148010A RU2015148010A RU2015148010A3 RU 2015148010 A3 RU2015148010 A3 RU 2015148010A3 RU 2015148010 A RU2015148010 A RU 2015148010A RU 2015148010 A RU2015148010 A RU 2015148010A RU 2015148010 A3 RU2015148010 A3 RU 2015148010A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811464P | 2013-04-12 | 2013-04-12 | |
| US61/811,464 | 2013-04-12 | ||
| PCT/US2014/034018 WO2014169278A1 (en) | 2013-04-12 | 2014-04-14 | Highly active nucleoside derivative for the treatment of hcv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015148010A RU2015148010A (ru) | 2017-05-15 |
| RU2015148010A3 true RU2015148010A3 (enExample) | 2018-04-28 |
Family
ID=50686233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015148006A RU2015148006A (ru) | 2013-04-12 | 2014-04-14 | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv |
| RU2015148010A RU2015148010A (ru) | 2013-04-12 | 2014-04-14 | Высокоактивное производное нуклеозида для лечения hcv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015148006A RU2015148006A (ru) | 2013-04-12 | 2014-04-14 | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9447132B2 (enExample) |
| EP (2) | EP2984097B1 (enExample) |
| JP (2) | JP2016518359A (enExample) |
| KR (2) | KR20160002896A (enExample) |
| CN (2) | CN105705511A (enExample) |
| AU (2) | AU2014250764A1 (enExample) |
| BR (2) | BR112015025716A2 (enExample) |
| CA (2) | CA2909270A1 (enExample) |
| ES (1) | ES2623287T3 (enExample) |
| RU (2) | RU2015148006A (enExample) |
| WO (2) | WO2014169278A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596979B (zh) | 2009-09-21 | 2014-12-10 | 吉里德科学公司 | 用于制备1’-取代碳核苷类似物的方法和中间体 |
| BR112013001553B1 (pt) | 2010-07-22 | 2021-01-12 | Gilead Sciences, Inc. | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
| CA2871547C (en) | 2012-05-25 | 2021-05-25 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| CN106459004B (zh) | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
| ES2841310T3 (es) * | 2014-06-24 | 2021-07-08 | Janssen Biopharma Inc | Nucleósidos, nucleótidos y análogos sustituidos para su uso en el tratamiento de infecciones virales |
| WO2016014527A2 (en) * | 2014-07-21 | 2016-01-28 | Achillion Pharmaceuticals, Inc. | Stabilized nucleotides for medical treatment |
| MX2017001459A (es) * | 2014-07-31 | 2017-05-23 | Sandoz Ag | Sintesis de fosforamidatos. |
| US10526363B2 (en) | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| US10118941B2 (en) | 2014-09-15 | 2018-11-06 | Medivir Ab | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| SG10202013032YA (en) | 2014-12-15 | 2021-02-25 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
| WO2016098123A2 (en) * | 2014-12-16 | 2016-06-23 | Laurus Labs Private Ltd | A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers |
| MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| US20190022116A1 (en) * | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
| WO2016134058A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
| WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| DK3265102T3 (da) | 2015-03-06 | 2025-10-13 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling |
| MX2018002707A (es) | 2015-09-02 | 2018-08-01 | Abbvie Inc | Derivados de tetrahidrofurano antivirales. |
| ES2918585T3 (es) | 2015-09-16 | 2022-07-19 | Gilead Sciences Inc | Métodos para el tratamiento de infecciones por el virus Arenaviridae |
| BR112018006206A2 (pt) * | 2015-09-29 | 2018-10-09 | Achillion Pharmaceuticals Inc | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa |
| WO2017100558A1 (en) | 2015-12-09 | 2017-06-15 | Research Triangle Institute | Improved apelin receptor (apj) agonists and uses thereof |
| WO2017118355A1 (zh) * | 2016-01-04 | 2017-07-13 | 上海长森药业有限公司 | 氘代HCV NS5b抑制剂核苷酸衍生物及其用途 |
| AU2017281531A1 (en) | 2016-06-24 | 2019-01-17 | Emory University | Phosphoramidates for the treatment of hepatitis B virus |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| EP3497111A2 (en) * | 2016-08-12 | 2019-06-19 | Janssen BioPharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN107759632A (zh) * | 2016-08-19 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 一种手性磷酸酯的制备方法 |
| BR112019004297A2 (pt) | 2016-09-07 | 2019-05-28 | Atea Pharmaceuticals Inc | método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica. |
| CN109790125B (zh) | 2016-09-16 | 2022-07-05 | 研究三角协会 | 四氢异喹啉κ阿片拮抗剂 |
| PE20190806A1 (es) | 2016-10-12 | 2019-06-10 | Res Triangle Inst | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos |
| AU2017382217B2 (en) | 2016-12-21 | 2021-07-08 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| CN108276463A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
| HRP20250266T1 (hr) | 2017-02-01 | 2025-04-25 | Atea Pharmaceuticals, Inc. | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN107987105B (zh) * | 2017-11-24 | 2019-10-01 | 无锡微色谱生物科技有限公司 | 一种可用于皮肤敷料的h2s给体化合物、海绵敷料和制备方法 |
| KR102139340B1 (ko) | 2017-12-01 | 2020-07-29 | 주식회사 엘지생활건강 | 즉시 주름 개선 및 탄력 증진용 화장료 조성물 |
| DK3706762T3 (da) | 2017-12-07 | 2024-12-16 | Univ Emory | N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| CN110835358B (zh) * | 2018-08-16 | 2022-08-05 | 上海复星星泰医药科技有限公司 | 一种索磷布韦中间体的制备方法 |
| KR20210049857A (ko) | 2018-08-20 | 2021-05-06 | 듀크 유니버시티 | 안과 질환 치료용 약물 조성물 및 치료 방법 |
| CN110221064A (zh) * | 2019-05-23 | 2019-09-10 | 南京农业大学 | 猪塞尼卡谷病毒elisa抗体检测方法及应用 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN111233929B (zh) * | 2020-02-28 | 2023-02-28 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物的氘代物及其制备方法和用途 |
| AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
| PL4157272T3 (pl) | 2020-05-29 | 2025-10-20 | Gilead Sciences, Inc. | Remdesiwir do leczenia zakażeń wirusowych |
| TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
| WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| EP4355319A4 (en) | 2021-06-17 | 2025-01-22 | ATEA Pharmaceuticals, Inc. | BENEFICIAL ANTI-HCV COMBINATION THERAPY |
| CN116217632A (zh) * | 2021-12-06 | 2023-06-06 | 广州谷森制药有限公司 | 一种氘代胞苷衍生物的制备方法 |
| TWI867455B (zh) | 2022-03-02 | 2024-12-21 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| WO2024020127A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| US5449664A (en) | 1988-11-21 | 1995-09-12 | Syntex (U.S.A.) Inc. | Antiviral agents |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| NZ286209A (en) | 1992-09-10 | 2000-09-29 | Isis Pharmaceuticals Inc | Use of HCV RNA anti-sense nucleotide sequences for treating Hepatitis C virus related disease |
| US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2171743C (en) | 1993-09-17 | 2007-11-20 | Norbert W. Bischofberger | Nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| CZ120699A3 (cs) | 1996-10-16 | 1999-09-15 | Icn Pharmaceuticals, Inc. | Monocyklická L-nukleosidová analoga a jejich využití |
| US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
| US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
| US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
| JP2002500880A (ja) | 1998-01-23 | 2002-01-15 | ニューバイオティックス インコーポレイテッド | 酵素に触媒される治療剤 |
| US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| MXPA02011691A (es) | 2000-05-26 | 2004-05-17 | Idenix Cayman Ltd | Metodos y composiciones para el tratamiento de flavivirus y pestivirus. |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| EP2251015B1 (en) | 2000-10-18 | 2013-02-20 | Gilead Pharmasset LLC | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| RS50236B (sr) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze |
| WO2002092006A2 (en) | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| JP2005522443A (ja) | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | 改変フッ素化ヌクレオシド類似体 |
| NZ536123A (en) | 2002-05-06 | 2006-09-29 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| JP2005533824A (ja) | 2002-06-28 | 2005-11-10 | イデニクス（ケイマン）リミテツド | フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン |
| MY140819A (en) | 2002-06-28 | 2010-01-29 | Idenix Caymans Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| US7772197B2 (en) | 2002-09-24 | 2010-08-10 | 1,3,5-Triazines for Treatment of Viral Diseases | 1,3,5-triazines for treatment of viral diseases |
| AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| PL2604620T5 (pl) | 2003-05-30 | 2024-10-14 | Gilead Pharmasset Llc | Zmodyfikowane fluorowane analogi nukleozydu |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| US7157434B2 (en) | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| KR100570697B1 (ko) | 2004-09-24 | 2006-04-12 | 삼성에스디아이 주식회사 | 연료 전지 시스템 및 이에 사용되는 개질기 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| JP5461009B2 (ja) | 2005-06-08 | 2014-04-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 非ペプチド及びペプチドｂｄｎｆニューロトロフィン類似体を用いた神経細胞生存促進法 |
| EP1928475B1 (en) | 2005-08-15 | 2018-05-23 | Riboscience LLC | Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides |
| US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
| US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
| JP2009526850A (ja) | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| CA2672944A1 (en) | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2008085508A2 (en) | 2007-01-05 | 2008-07-17 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| AU2008210411A1 (en) | 2007-01-31 | 2008-08-07 | Alios Biopharma, Inc. | 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
| GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2009058800A2 (en) | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| WO2009086201A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents |
| WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
| US8415321B2 (en) | 2008-04-15 | 2013-04-09 | Raymond F. Schinazi | Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections |
| EP2476690A1 (en) | 2008-07-02 | 2012-07-18 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2318423B1 (en) | 2008-08-08 | 2014-05-07 | ScinoPharm Taiwan, Ltd. | Process for making 5-azacytosine nucleosides and their derivatives |
| GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
| PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| BRPI0922912A8 (pt) | 2008-12-10 | 2018-01-02 | Achillion Pharmaceuticals Inc | peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral |
| EP2364310B1 (en) | 2008-12-10 | 2015-07-29 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| KR20110120886A (ko) | 2009-01-09 | 2011-11-04 | 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 | 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체 |
| CN102395590A (zh) | 2009-02-06 | 2012-03-28 | Rfs制药公司 | 用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药 |
| US20100240604A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| EP2408306A4 (en) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
| JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| MX2012011171A (es) | 2010-03-31 | 2013-02-01 | Gilead Pharmasset Llc | Fosforamidatos de nucleosido. |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| AR094621A1 (es) | 2010-04-01 | 2015-08-19 | Idenix Pharmaceuticals Inc | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales |
| WO2012012465A1 (en) * | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| WO2012016994A1 (en) | 2010-08-04 | 2012-02-09 | Herbert Schott | Bone-targeting bisphosphonate duplex drugs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| BR112013005872A2 (pt) * | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
| AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
| WO2012062869A1 (en) | 2010-11-10 | 2012-05-18 | Janssen Products, Lp | Uracyl spirooxetane nucleoside phosphoramidates |
| JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
| WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| EP2658857B1 (en) | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
| CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| EP2697241B1 (en) | 2011-04-13 | 2019-06-12 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP2696681B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CA2836579A1 (en) | 2011-05-19 | 2012-11-22 | Rfs Pharma, Llc | Purine monophosphate prodrugs for treatment of viral infections |
| KR101931311B1 (ko) | 2011-05-27 | 2018-12-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | Ｈｃｖ 감염 치료에 유용한 치환된 앨리팬, 시클로팬, 헤테라팬, 헤테로팬, 헤테로-헤테라팬 및 메탈로센 |
| US20140113958A1 (en) | 2011-06-30 | 2014-04-24 | Stella Aps | HCV Combination Therapy |
| US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
| WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
| HK1198869A1 (en) | 2011-08-24 | 2015-06-19 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
| US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2847892A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| MX2014003180A (es) | 2011-09-16 | 2014-04-25 | Abbvie Inc | Metodos para tratar vhc. |
| US8575119B2 (en) | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013066991A1 (en) | 2011-10-31 | 2013-05-10 | Inhibitex, Inc. | Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease |
| WO2013090420A2 (en) | 2011-12-12 | 2013-06-20 | Catabasis Pharmaceuticals, Inc. | Fatty acid antiviral conjugates and their uses |
| EP2797594A1 (en) | 2011-12-28 | 2014-11-05 | AbbVie Inc. | Methods for treating hcv |
| HK1201186A1 (en) | 2011-12-29 | 2015-08-28 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
-
2014
- 2014-04-14 CN CN201480033500.3A patent/CN105705511A/zh active Pending
- 2014-04-14 AU AU2014250764A patent/AU2014250764A1/en not_active Abandoned
- 2014-04-14 CN CN201480033503.7A patent/CN105377868A/zh active Pending
- 2014-04-14 US US14/252,290 patent/US9447132B2/en not_active Expired - Fee Related
- 2014-04-14 US US14/252,494 patent/US20140309164A1/en not_active Abandoned
- 2014-04-14 EP EP14722955.3A patent/EP2984097B1/en active Active
- 2014-04-14 ES ES14722955.3T patent/ES2623287T3/es active Active
- 2014-04-14 WO PCT/US2014/034018 patent/WO2014169278A1/en not_active Ceased
- 2014-04-14 CA CA2909270A patent/CA2909270A1/en not_active Abandoned
- 2014-04-14 KR KR1020157032206A patent/KR20160002896A/ko not_active Withdrawn
- 2014-04-14 RU RU2015148006A patent/RU2015148006A/ru not_active Application Discontinuation
- 2014-04-14 JP JP2016507702A patent/JP2016518359A/ja not_active Ceased
- 2014-04-14 JP JP2016507703A patent/JP2016522172A/ja active Pending
- 2014-04-14 CA CA2909273A patent/CA2909273A1/en not_active Abandoned
- 2014-04-14 BR BR112015025716A patent/BR112015025716A2/pt not_active IP Right Cessation
- 2014-04-14 KR KR1020157032200A patent/KR20160003700A/ko not_active Withdrawn
- 2014-04-14 AU AU2014250762A patent/AU2014250762A1/en not_active Abandoned
- 2014-04-14 RU RU2015148010A patent/RU2015148010A/ru not_active Application Discontinuation
- 2014-04-14 WO PCT/US2014/034021 patent/WO2014169280A2/en not_active Ceased
- 2014-04-14 EP EP14724944.5A patent/EP2984098A2/en not_active Withdrawn
- 2014-04-14 BR BR112015025766A patent/BR112015025766A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160003700A (ko) | 2016-01-11 |
| AU2014250762A1 (en) | 2015-10-29 |
| JP2016518359A (ja) | 2016-06-23 |
| RU2015148006A3 (enExample) | 2018-08-01 |
| CA2909273A1 (en) | 2014-10-16 |
| BR112015025766A2 (pt) | 2017-10-17 |
| CA2909270A1 (en) | 2014-10-16 |
| CN105377868A (zh) | 2016-03-02 |
| US9447132B2 (en) | 2016-09-20 |
| RU2015148010A (ru) | 2017-05-15 |
| AU2014250764A1 (en) | 2015-10-29 |
| KR20160002896A (ko) | 2016-01-08 |
| US20140309164A1 (en) | 2014-10-16 |
| EP2984098A2 (en) | 2016-02-17 |
| JP2016522172A (ja) | 2016-07-28 |
| WO2014169280A2 (en) | 2014-10-16 |
| BR112015025716A2 (pt) | 2017-07-18 |
| EP2984097B1 (en) | 2017-03-29 |
| CN105705511A (zh) | 2016-06-22 |
| WO2014169278A1 (en) | 2014-10-16 |
| RU2015148006A (ru) | 2017-05-18 |
| ES2623287T3 (es) | 2017-07-10 |
| EP2984097A1 (en) | 2016-02-17 |
| WO2014169280A3 (en) | 2014-12-18 |
| US20140309189A1 (en) | 2014-10-16 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180813 |